FindMyKOL
Clinical trialNCT02000089RecruitingPhase 3Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089 is a phase 3 interventional trial sponsored by Johns Hopkins University. As of 21 Nov 2026, it is recruiting participants. It studies Secretin in Gene Mutation, Germline Mutation Carrier and 3 more conditions. The registry lists an enrollment of 9,000 participants at 9 sites in 1 country. The registry lists a start date of 6 Jan 2014 and a primary completion date of 31 Dec 2028. One of its registered investigators has a FindMyKOL profile.

SponsorJohns Hopkins University →Enrollment9,000Gene MutationGermline Mutation CarrierLynch SyndromePancreas CancerPeutz-Jeghers Syndrome (PJS)
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02000089
FieldValue
Registry IDNCT02000089
StatusRecruiting
PhasePhase 3
Study typeInterventional trial
Lead sponsorJohns Hopkins University
Enrollment9,000
Registered sites9
Countries1
ConditionsGene Mutation, Germline Mutation Carrier, Lynch Syndrome, Pancreas Cancer and Peutz-Jeghers Syndrome (PJS)
DrugsSecretin
Start6 Jan 2014
Primary completion31 Dec 2028
Study completion30 Jun 2029
Last update posted22 Oct 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Connecticut, United States1 site, 1 recruiting
  • Yale University

    New Haven

    James Farrell, MD
    Recruiting
Maryland, United States1 site, 1 recruiting
  • Johns Hopkins Hospital

    Baltimore

    Marcia I Canto, MDMichael Goggins, MD
    Recruiting
Massachusetts, United States1 site, 1 recruiting
  • Dana Farber Cancer Center, Harvard University

    Boston

    Matthew Yurgelun, MDSapna Syngal, MD
    Recruiting
Michigan, United States1 site, 1 recruiting
  • University of Michigan

    Ann Arbor

    Elena Stoffel, MD
    Recruiting
New York, United States2 sites, 2 recruiting
  • Columbia University Medical Center

    New York

    Fay Kastrinos, MD
    Recruiting
  • Nyu Langone Medical Center

    New York

    Tamas Gonda, MD
    Recruiting
Ohio, United States1 site, 1 recruiting
  • Case Comprehensive Cancer Center, Case Western Medical Reserve

    Cleveland

    Amitabh Chak, MD
    Recruiting
Pennsylvania, United States2 sites, 2 recruiting
  • University of Pennsylvania

    Philadelphia

    Bryson Katona, MD
    Recruiting
  • University of Pittsburgh

    Pittsburgh

    Randall Brand, MD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichigan: 1 site, 1 recruitingMI1New York: 2 sites, 2 recruitingNY2Massachusetts: 1 site, 1 recruitingMA1Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhio: 1 site, 1 recruitingOH1Pennsylvania: 2 sites, 2 recruitingPA2New JerseyNJConnecticut: 1 site, 1 recruitingCT1CaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 site, 1 recruitingMD1DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Secretin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT02000089

Each answer restates registry values shown on this page.

What is NCT02000089?

NCT02000089 is a phase 3 interventional trial sponsored by Johns Hopkins University. It studies Secretin in Gene Mutation, Germline Mutation Carrier and 3 more conditions.

Is NCT02000089 recruiting?

As of 21 Nov 2026, it is recruiting participants. 9 of its 9 sites list their own status as recruiting.

Who leads NCT02000089?

The registry names Michael Goggins, MD (principal investigator, Johns Hopkins University) as the overall official.

Where does NCT02000089 run?

The registry lists 9 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT02000089 study?

The registered drug and biological interventions are Secretin.

When is NCT02000089 expected to complete?

The registry lists a primary completion date of 31 Dec 2028 and a study completion date of 30 Jun 2029. The sponsor last updated the record on 22 Oct 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.